Formosa Laboratories, Inc.

Taiwan Stock Exchange 4746.TW

Formosa Laboratories, Inc. Receivables for the year ending December 31, 2023: USD 31.27 M

Formosa Laboratories, Inc. Receivables is USD 31.27 M for the year ending December 31, 2023, a 15.90% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Formosa Laboratories, Inc. Receivables for the year ending December 31, 2022 was USD 26.98 M, a -3.34% change year over year.
Formosa Laboratories, Inc. Receivables for the year ending December 31, 2021 was USD 27.91 M, a 0.04% change year over year.
Formosa Laboratories, Inc. Receivables for the year ending December 31, 2020 was USD 27.90 M, a -5.90% change year over year.
Formosa Laboratories, Inc. Receivables for the year ending December 31, 2019 was USD 29.65 M, a 3.70% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Taiwan Stock Exchange: 4746.TW

Formosa Laboratories, Inc.

CEO	Dr. Chen-Yu Cheng Ph.D.
IPO Date	Feb. 28, 2011
Location	Taiwan
Headquarters	36 Hoping Street
Employees	867
Sector	Health Care
Industries Pharmaceuticals

Description

Formosa Laboratories, Inc. produces and sells active pharmaceutical ingredients (APIs) worldwide. The company offers APIs in the areas of anticancer, anti-inflammatory and analgesic agents, MRI enhancing agents, cholesterol and phosphate binders, CNS agents, immunomodulators, respiratory agents, steroids, vitamin D derivatives, and antibiotics. It also provides contract development and manufacturing services; solutions for manufacturing antibody-drug conjugates; and injectable manufacturing services. The company was founded in 1995 and is based in Taoyuan City, Taiwan.

Key trends

Past 5 years